Waters Corporation
New York Stock ExchangeRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Waters Corporation (NYSE: WAT), founded in 1958 and headquartered in Milford, Massachusetts, develops, manufactures, and markets analytical instruments, chromatography columns, and other consumables for the life sciences, pharmaceutical, biopharmaceutical, chemical, food, environmental, and clinical diagnostics industries worldwide. The company offers high-performance liquid chromatography (HPLC) and ultra-performance liquid chromatography (UPLC) systems such as the ACQUITY Premier and Alliance iS series; mass spectrometry instruments including the Xevo G3 QTof, Xevo TQ Absolute, SELECT SERIES MRT, and BioAccord LC-MS; gel permeation and size exclusion chromatography solutions; thermal analysis and rheology products through its TA Instruments division; light-scattering devices from Wyatt Technology; software platforms like Empower and waters_connect for data management and compliance; and related consumables, columns, detectors, and accessories used in drug discovery, development, manufacturing, food safety testing, environmental monitoring, and materials science applications across more than 100 countries with 12 manufacturing facilities and operations in 35 countries. Recent developments include the 2025 acquisition of Halo Labs to expand its biological analysis portfolio for advanced characterization in drug development; the July 2025 agreement to combine with BD's Biosciences and Diagnostic Solutions business in a $17.5 billion all-stock merger creating a leader in regulated life science and high-volume diagnostics testing; and the 2023 acquisition of Wyatt Technology enhancing its capabilities in macromolecular characterization and complex mixture analysis.
Waters Introduces Unrivaled Sensitivity and Speed to Benchtop HRMS with Xevo MRT P10 MS, Accelerating Multiomics Research
Waters Unveils Cyclic IMS P20 MS: The New Benchmark in Structural and Spatial Omics
Carnival: Calm Waters Despite Fuel Price Headwinds
Waters Corporation to Present at the Jefferies Global Healthcare Conference
Understanding Waters (WAT) Reliance on International Revenue
WAT Q1 Earnings Beat Estimates, BD Acquisition Aids Revenues
Conrad Industries Is Worth The Volatile Waters The Industry Faces
Waters Corporation (WAT) Q1 2026 Earnings Call Transcript
Waters raises annual profit forecast as biosciences unit drives growth
Waters (WAT) Beats Q1 Earnings and Revenue Estimates
Waters Corporation (NYSE: WAT) Reports First Quarter 2026 Financial Results
Teleflex (TFX) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
Will Waters (WAT) Beat Estimates Again in Its Next Earnings Report?
Waters (WAT) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Waters Corporation Schedules First Quarter 2026 Earnings Conference Call
Waters Debuts Industry-First Extended-Range MALS Detector for UHPLC/UPLC, Powering Rapid Characterization of Large Molecules
Brown Lisle Cummings Inc. Increases Holdings in Waters Corporation $WAT
Waters Stock Shoots Higher As FDA Clears At-Home Cervical Cancer Screening Kit
Waters Announces FDA Clearance of the Most Comprehensive At-Home Cervical Cancer Screening Tool, the Onclarity HPV Self-Collection Kit and FDA-Approved HPV Assay
ClearBridge Dividend Strategy Q1 2026 Portfolio Positioning